Using clinical data from an integrated health care delivery system with centralized GDM management and comprehensive information on glycemic control after GDM diagnosis, we did not find evidence of a difference in the perinatal outcomes examined for glyburide compared with insulin as first-line medication therapy. This evidence concerns the gene INS and gestational diabetes.